388 related articles for article (PubMed ID: 31342441)
21. The versatility of oligonucleotides as potential therapeutics.
Eckstein F
Expert Opin Biol Ther; 2007 Jul; 7(7):1021-34. PubMed ID: 17665991
[TBL] [Abstract][Full Text] [Related]
22. Overcoming the challenges of tissue delivery for oligonucleotide therapeutics.
Gökirmak T; Nikan M; Wiechmann S; Prakash TP; Tanowitz M; Seth PP
Trends Pharmacol Sci; 2021 Jul; 42(7):588-604. PubMed ID: 34020790
[TBL] [Abstract][Full Text] [Related]
23. Next-generation therapeutics for rare genetic disorders.
Sankar A; Y S RK; Singh A; Roy R; Shukla R; Verma B
Mutagenesis; 2024 Apr; 39(3):157-171. PubMed ID: 38332115
[TBL] [Abstract][Full Text] [Related]
24. Antisense technology: an emerging platform for cardiovascular disease therapeutics.
Lee RG; Crosby J; Baker BF; Graham MJ; Crooke RM
J Cardiovasc Transl Res; 2013 Dec; 6(6):969-80. PubMed ID: 23856914
[TBL] [Abstract][Full Text] [Related]
25. An Insight on RNA Based Therapeutics and Vaccines: Challenges and Opportunities.
Batra K; Maan S; Sehrawat A
Curr Top Med Chem; 2021; 21(32):2851-2855. PubMed ID: 34792013
[TBL] [Abstract][Full Text] [Related]
26. Design and In Vitro Use of Antisense Oligonucleotides to Correct Pre-mRNA Splicing Defects in Inherited Retinal Dystrophies.
Garanto A; Collin RWJ
Methods Mol Biol; 2018; 1715():61-78. PubMed ID: 29188506
[TBL] [Abstract][Full Text] [Related]
27. RNA Therapeutics - Research and Clinical Advancements.
Feng R; Patil S; Zhao X; Miao Z; Qian A
Front Mol Biosci; 2021; 8():710738. PubMed ID: 34631795
[TBL] [Abstract][Full Text] [Related]
28. Specificity of oligonucleotide gene therapy (OGT) agents.
Nedorezova DD; Dubovichenko MV; Belyaeva EP; Grigorieva ED; Peresadina AV; Kolpashchikov DM
Theranostics; 2022; 12(16):7132-7157. PubMed ID: 36276652
[TBL] [Abstract][Full Text] [Related]
29. [Therapeutic oligonucleotides: a review].
Wang X; Xian J; Chen G; Peng H
Sheng Wu Gong Cheng Xue Bao; 2018 May; 34(5):664-675. PubMed ID: 29893074
[TBL] [Abstract][Full Text] [Related]
30. Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies.
Taniguchi H; Suzuki Y; Imai K; Adachi Y
Cancer Sci; 2022 Sep; 113(9):2952-2961. PubMed ID: 35701833
[TBL] [Abstract][Full Text] [Related]
31. Dermal/transdermal delivery of small interfering RNA and antisense oligonucleotides- advances and hurdles.
Ita K
Biomed Pharmacother; 2017 Mar; 87():311-320. PubMed ID: 28064104
[TBL] [Abstract][Full Text] [Related]
32. Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides.
Senn C; Hangartner C; Moes S; Guerini D; Hofbauer KG
Eur J Pharmacol; 2005 Oct; 522(1-3):30-7. PubMed ID: 16213482
[TBL] [Abstract][Full Text] [Related]
33. Small non-coding RNA therapeutics for cardiovascular disease.
Shah AM; Giacca M
Eur Heart J; 2022 Nov; 43(43):4548-4561. PubMed ID: 36106499
[TBL] [Abstract][Full Text] [Related]
34. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
Oberbauer R
Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
[TBL] [Abstract][Full Text] [Related]
35. Gene Delivery in Lipid Research and Therapies.
De Giorgi M; Lagor WR
Methodist Debakey Cardiovasc J; 2019; 15(1):62-69. PubMed ID: 31049151
[TBL] [Abstract][Full Text] [Related]
36. RNA therapeutics for metabolic disorders.
Vu TD; Lin SC; Wu CC; Chu DT
Prog Mol Biol Transl Sci; 2024; 203():181-196. PubMed ID: 38359998
[TBL] [Abstract][Full Text] [Related]
37. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides.
Sierakowska H; Sambade MJ; Agrawal S; Kole R
Proc Natl Acad Sci U S A; 1996 Nov; 93(23):12840-4. PubMed ID: 8917506
[TBL] [Abstract][Full Text] [Related]
38. Splicing-correcting therapeutic approaches for retinal dystrophies: where endogenous gene regulation and specificity matter.
Bacchi N; Casarosa S; Denti MA
Invest Ophthalmol Vis Sci; 2014 May; 55(5):3285-94. PubMed ID: 24867912
[TBL] [Abstract][Full Text] [Related]
39. Nucleic Acid Therapies for Cystic Fibrosis.
Sasaki S; Guo S
Nucleic Acid Ther; 2018 Feb; 28(1):1-9. PubMed ID: 29160746
[TBL] [Abstract][Full Text] [Related]
40. Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System.
Mendonça MCP; Kont A; Aburto MR; Cryan JF; O'Driscoll CM
Mol Pharm; 2021 Apr; 18(4):1491-1506. PubMed ID: 33734715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
